Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
February 21 2022 - 4:00PM
Business Wire
Mark Rothera steps down as President and
CEO
Silence Therapeutics plc, Nasdaq: SLN
(“Silence” or “the Company”), a leader in the discovery,
development and delivery of novel short interfering ribonucleic
acid (“siRNA”) therapeutics for the treatment of diseases with
significant unmet medical need, today announced that Craig Tooman,
previously Chief Financial Officer (“CFO”), has been appointed
President, Chief Executive Officer (“CEO”) and Board member of
Silence, and Mark Rothera has stepped down as President, CEO and
Board member, effective immediately. Rhonda Hellums, previously
Vice President, Finance, has been appointed CFO.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220221005328/en/
Craig Tooman President & CEO Silence
Therapeutics plc (Photo: Business Wire)
“On behalf of the Board, I would like to thank Mark for his
contributions over the last 18 months and we wish him well,” said
Iain Ross, Chairman at Silence. “Craig is a seasoned leader who
understands all aspects of our corporate strategy and the immediate
need to maximize our potential going forward. With Craig as CEO and
Dr. Giles Campion leading our exceptional research and development
efforts, I am confident that Silence is now well-positioned to
capitalize appropriately on the positive data we recently reported
with SLN360 and ensure long-term shareholder value.”
Craig Tooman, President and CEO, commented, “I am extremely
pleased to have the opportunity to lead Silence and have come to
appreciate the strong stewardship of Iain Ross as Chairman of the
Board. I look forward to working with Giles, the executive team,
and full Board, to take Silence through its next exciting stage of
growth.”
Craig Tooman joined Silence in January 2021, and brings more
than 30 years of operational, financial and merger and acquisition
(“M&A”) experience. Most recently, he was Chief Operating
Officer and CFO at Vyome Therapeutics, and prior to this was CEO of
Aratana Therapeutics where he successfully negotiated a merger with
Elanco. Before Aratana, Mr. Tooman was the CEO of Avanzar Medical
Inc., a private oncology company, and CFO of Enzon Pharmaceuticals
until its acquisition by Sigma Tau. Prior to that he led the $1.1
billion M&A initiative and integration of ILEX Oncology and
Genzyme Corporation. He also held key positions at Pharmacia and
Upjohn. Mr. Tooman currently serves on the Supervisory Board and
Audit Committee of CureVac, which accomplished a successful initial
public offering on Nasdaq in August of 2020. He holds a BA in
Economics from Kalamazoo College and an MBA from the University of
Chicago.
Rhonda Hellums has over 25 years of corporate finance,
accounting, strategic planning, M&A, treasury management,
investor and public relations. Prior to joining Silence in April
2021, she held management positions at several large healthcare
companies, including KCI (now 3M+KCI) and Genzyme Corporation. She
previously served as CFO of Deer Oaks Mental Health and prior to
that, CFO of Aratana Therapeutics, a publicly traded pet
therapeutics company. Ms. Hellums received her BBA degree in
Accounting and Information Systems and MBA from the University of
Texas at San Antonio.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include SLN360 designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
high levels of lipoprotein(a) and SLN124 designed to address rare
hematological diseases. Silence also maintains ongoing research and
development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Hansoh Pharma, among others. For more
information, please visit
https://www.silence-therapeutics.com/.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and other securities laws, including
with respect to the Company’s clinical and commercial prospects,
regulatory approvals of the Company’s product candidates, potential
partnerships or collaborations, the initiation or completion of the
Company’s clinical trials and the anticipated timing or outcomes of
data reports from the Company’s clinical trials. These
forward-looking statements are not historical facts but rather are
based on the Company's current assumptions, beliefs, expectations,
estimates and projections about its industry. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements, including those risks identified in
the Company’s most recent Admission Document, its amended Annual
Report on Form 20-F filed with the U.S. Securities and Exchange
Commission (the “SEC”) on April 29, 2021 and its Current Report on
Form 6-K filed with the SEC on November 16, 2021. The Company
cautions security holders and prospective security holders not to
place undue reliance on these forward-looking statements, which
reflect the view of the Company only as of the date of this
announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220221005328/en/
Silence Therapeutics plc Gem Hopkins, Head of IR and
Corporate Communications Tel: +1 (646) 637-3208
ir@silence-therapeutics.com
US Media Relations MKC Strategies Mary Conway Tel:
+1 (516) 606-6545 mconway@mkcstrategies.com
European Media Relations Consilium Strategic
Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh
Tel: +44 (0) 20 3709 5700
silencetherapeutics@consilium-comms.com
Spectralink (NASDAQ:SLNK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Spectralink (NASDAQ:SLNK)
Historical Stock Chart
From Jul 2023 to Jul 2024